Logo image of BMGL

BASEL MEDICAL GROUP LTD (BMGL) Stock Fundamental Analysis

NASDAQ:BMGL - Nasdaq - VGG0864B1031 - Common Stock - Currency: USD

4.17  +0.1 (+2.46%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to BMGL. BMGL was compared to 102 industry peers in the Health Care Providers & Services industry. BMGL has an excellent financial health rating, but there are some minor concerns on its profitability. BMGL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year BMGL was profitable.
BMGL had a positive operating cash flow in the past year.
BMGL Yearly Net Income VS EBIT VS OCF VS FCFBMGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 1M 2M 3M 4M

1.2 Ratios

BMGL has a Return On Assets of 12.71%. This is amongst the best in the industry. BMGL outperforms 95.10% of its industry peers.
BMGL has a Return On Equity of 27.41%. This is amongst the best in the industry. BMGL outperforms 93.14% of its industry peers.
BMGL has a better Return On Invested Capital (31.78%) than 99.02% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BMGL is significantly above the industry average of 9.13%.
The last Return On Invested Capital (31.78%) for BMGL is above the 3 year average (29.84%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 12.71%
ROE 27.41%
ROIC 31.78%
ROA(3y)12.01%
ROA(5y)N/A
ROE(3y)37.76%
ROE(5y)N/A
ROIC(3y)29.84%
ROIC(5y)N/A
BMGL Yearly ROA, ROE, ROICBMGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 10 20 30 40 50

1.3 Margins

BMGL has a better Profit Margin (20.62%) than 99.02% of its industry peers.
Looking at the Operating Margin, with a value of 44.01%, BMGL belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
OM 44.01%
PM (TTM) 20.62%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BMGL Yearly Profit, Operating, Gross MarginsBMGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 10 20 30 40

More info and screens

9

2. Health

2.1 Basic Checks

BMGL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for BMGL remains at a similar level compared to 1 year ago.
The debt/assets ratio for BMGL has been reduced compared to a year ago.
BMGL Yearly Shares OutstandingBMGL Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M
BMGL Yearly Total Debt VS Total AssetsBMGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 5M 10M 15M

2.2 Solvency

An Altman-Z score of 7.69 indicates that BMGL is not in any danger for bankruptcy at the moment.
BMGL has a Altman-Z score of 7.69. This is amongst the best in the industry. BMGL outperforms 93.14% of its industry peers.
The Debt to FCF ratio of BMGL is 1.71, which is an excellent value as it means it would take BMGL, only 1.71 years of fcf income to pay off all of its debts.
BMGL has a better Debt to FCF ratio (1.71) than 84.31% of its industry peers.
A Debt/Equity ratio of 0.56 indicates that BMGL is somewhat dependend on debt financing.
BMGL has a Debt to Equity ratio (0.56) which is in line with its industry peers.
Even though the debt/equity ratio score it not favorable for BMGL, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 1.71
Altman-Z 7.69
ROIC/WACC3.68
WACC8.63%
BMGL Yearly LT Debt VS Equity VS FCFBMGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2M 4M 6M

2.3 Liquidity

A Current Ratio of 2.26 indicates that BMGL has no problem at all paying its short term obligations.
BMGL has a Current ratio of 2.26. This is in the better half of the industry: BMGL outperforms 77.45% of its industry peers.
BMGL has a Quick Ratio of 2.25. This indicates that BMGL is financially healthy and has no problem in meeting its short term obligations.
BMGL has a better Quick ratio (2.25) than 77.45% of its industry peers.
Industry RankSector Rank
Current Ratio 2.26
Quick Ratio 2.25
BMGL Yearly Current Assets VS Current LiabilitesBMGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.25% over the past year.
BMGL shows a small growth in Revenue. In the last year, the Revenue has grown by 3.60%.
EPS 1Y (TTM)16.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.25%
Revenue 1Y (TTM)3.6%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.6%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BMGL Yearly Revenue VS EstimatesBMGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 46.33, BMGL can be considered very expensive at the moment.
The rest of the industry has a similar Price/Earnings ratio as BMGL.
BMGL's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.22.
Industry RankSector Rank
PE 46.33
Fwd PE N/A
BMGL Price Earnings VS Forward Price EarningsBMGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

The rest of the industry has a similar Enterprise Value to EBITDA ratio as BMGL.
BMGL's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 40.58
EV/EBITDA 20.39
BMGL Per share dataBMGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.1 0.2 0.3 0.4

4.3 Compensation for Growth

BMGL has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BMGL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BASEL MEDICAL GROUP LTD

NASDAQ:BMGL (5/2/2025, 8:00:01 PM)

4.17

+0.1 (+2.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap78.35M
AnalystsN/A
Price TargetN/A
Short Float %0.56%
Short Ratio0.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 46.33
Fwd PE N/A
P/S 10.1
P/FCF 40.58
P/OCF 40.45
P/B 13.42
P/tB 13.42
EV/EBITDA 20.39
EPS(TTM)0.09
EY2.16%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.1
FCFY2.46%
OCF(TTM)0.1
OCFY2.47%
SpS0.41
BVpS0.31
TBVpS0.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 12.71%
ROE 27.41%
ROCE 48.37%
ROIC 31.78%
ROICexc 38.41%
ROICexgc 38.41%
OM 44.01%
PM (TTM) 20.62%
GM N/A
FCFM 24.89%
ROA(3y)12.01%
ROA(5y)N/A
ROE(3y)37.76%
ROE(5y)N/A
ROIC(3y)29.84%
ROIC(5y)N/A
ROICexc(3y)34.59%
ROICexc(5y)N/A
ROICexgc(3y)34.59%
ROICexgc(5y)N/A
ROCE(3y)47.14%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 1.71
Debt/EBITDA 0.86
Cap/Depr 1.49%
Cap/Sales 0.08%
Interest Coverage 25.11
Cash Conversion 50.67%
Profit Quality 120.68%
Current Ratio 2.26
Quick Ratio 2.25
Altman-Z 7.69
F-Score6
WACC8.63%
ROIC/WACC3.68
Cap/Depr(3y)5.99%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.32%
Cap/Sales(5y)N/A
Profit Quality(3y)134.28%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.25%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)3.6%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.49%
OCF growth 3YN/A
OCF growth 5YN/A